Affimed N.V. - AFMD STOCK NEWS

Affimed N.V. (AFMD) to release full year 2023 results and corporate update on March 28, 2024. Conference call scheduled for investors to discuss the latest developments in the clinical-stage immuno-oncology company.

Affimed N.V. announces a 1-for-10 reverse stock split of its outstanding common shares to maintain NASDAQ listing compliance. Shareholders will receive cash payments in lieu of fractional shares.

Affimed N.V. (AFMD) provides update on AFM24-102 Phase 1/2a study for EGFR-wildtype (wt) non-small cell lung cancer (NSCLC), showing promising responses in heavily pre-treated patients. The study will be expanded to 40 patients, with data from both EGFRwt and EGFRmut cohorts expected in H1 2024.

Affimed N.V. (AFMD) announced that Dr. Adi Hoess is stepping down as CEO and Management Board Member, with Dr. Andreas Harstrick appointed as Interim CEO. The company is undergoing a strategic restructuring, reducing headcount by up to 50% and extending cash runway into H2 2025. Affimed will focus on advancing clinical programs and confirms guidance on data readouts for AFM24-102 and LuminICE-203 in H1 2024.

Affimed N.V. (Nasdaq: AFMD) has announced a definitive agreement to sell its subsidiary, AbCheck s.r.o., to Ampersand Biomedicines for $6 million, including $5 million in cash and $1 million in Ampersand common stock. Affimed will also receive milestone payments from a pre-existing partnership with AbCheck.

Affimed N.V. (Nasdaq: AFMD) announced interim safety and efficacy data on its innate cell engager (ICE®) AFM24 from the ongoing AFM24-102 combination study with atezolizumab, an anti-PD-L1 checkpoint inhibitor, in patients with advanced EGFR-expressing solid tumors. The data includes 15 heavily pre-treated patients from the EGFR-wildtype non-small cell lung cancer (NSCLC) expansion cohort, with responses observed in 4 of 15 patients, including 1 confirmed partial response (PR), 1 unconfirmed complete response (CR) awaiting confirmation, 2 unconfirmed PRs awaiting confirmation, and an additional 7 of 15 patients exhibiting stable disease (SD) leading to a disease control rate of 73%. Tumor shrinkage was observed in 7 of 15 (47%) patients. The majority of patients experienced only mild to moderate treatment-related adverse events, confirming a well-manageable safety profile in combination with atezolizumab. Affimed also announced that it has discontinued enrollment in AFM24-102 into the gastric cancer cohort and the basket cohort evaluating pancreatic cancer, biliary tract cancer, and hepatocellular carcinoma.

Affimed N.V. (AFMD) announced updated data on its lead innate cell engager (ICE®) acimtamig, presented at the American Society of Hematology (ASH) 2023 Annual Meeting. The objective response rate (ORR) for r/r Hodgkin lymphoma (HL) patients was 97%, with a complete response (CR) rate of 78%. The median event-free survival (EFS) was 9.8 months, with 84% of patients alive at 12 months. The treatment was well tolerated with no instances of cytokine release syndrome (CRS), graft versus host disease (GvHD) or immune effector cell-associated neurotoxicity syndrome (ICANS).

Affimed N.V. (Nasdaq: AFMD) to review clinical data of acimtamig in combination with cord-blood derived NK cells and provide progress update on the LuminICE-203 and AFM24-102 trials at ASH 2023. Conference call/webcast on December 11, 2023, to discuss the clinical data.

Affimed N.V. (Nasdaq: AFMD) reported financial results and clinical progress for Q3 2023. Initiatives include LuminICE-203 study, fast-track designation for acimtamig, FDA feedback, AFM13-104 presentation, AFM24 combination study, AFM28 progress, cash runway into 2025, and upcoming milestones.